FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287094865> ?p ?o ?g. }

• W4287094865 endingPage "1236" @default.
• W4287094865 startingPage "1225" @default.
• W4287094865 abstract "The COVID-19 pandemic poses an unprecedented threat to global business relationships and dynamics. The pharmacovigilance function of pharmaceutical companies is particularly susceptible to changing external pressures because of its highly structured compliance activities. We conducted an industry-wide survey to provide insights on how the pharmacovigilance function responded to the challenges posed by the pandemic. We compared smaller companies and larger companies regarding impact on portfolios and operational activity metrics.We conducted a survey through the Navitas Life Science annual benchmark of pvnetTM, a network of large enterprise (LE) companies, and pvconnectTM, a network of small and medium enterprise (SME) companies, using an online surveying tool during the first quarter of 2021. We collected information on pharmacovigilance activities, including quantitative measures of workload, costs, and key performance indicators, and qualitative data on the effects of the pandemic on product portfolios and operations.Survey questions were posed to LE (pvnet) network members (n = 12) and SME (pvconnect) network members (n = 18) for the period from January 1 through December 31, 2020. The date of data collection was March 26, 2021. Descriptive median values of parameter metrics included the following: revenue ($28.4 billion for LE companies and $1.6 billion for SME companies), number of products (127 for LE companies and 19 for SME companies), and volume of individual case safety reports (391,000 for LE companies and 13,000 for SME companies). SME companies reported a greater impact on 2 survey categories, remote working and employee well-being, than did LE companies. However, LE companies reported a greater impact than did SME companies on all other survey categories: effect on strategic priorities, shift in product focus, workload changes, changes in sourcing model, effect on case reporting compliance, effect on business continuity, changes in pharmacovigilance technology strategy, impact of interactions with health authorities, effect on resource capacity, and impact on recruitment.Four major themes emerge from this survey: (1) shift to remote working, (2) recognition of the impact on employee well-being, (3) shift in strategic priorities, and (4) newly recognized aspects of risk mitigation. The COVID-19 pandemic has had a marked effect on every aspect of pharmaceutical companies' pharmacovigilance functions, although the effects appear to be different for LE companies than for SME companies." @default.
• W4287094865 created "2022-07-25" @default.
• W4287094865 creator A5027165022 @default.
• W4287094865 creator A5034887228 @default.
• W4287094865 creator A5040798720 @default.
• W4287094865 creator A5053168114 @default.
• W4287094865 creator A5090884900 @default.
• W4287094865 date "2022-09-01" @default.
• W4287094865 modified "2023-09-26" @default.
• W4287094865 title "Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry Survey" @default.
• W4287094865 cites W2886532741 @default.
• W4287094865 cites W2989157027 @default.
• W4287094865 cites W3032856638 @default.
• W4287094865 cites W3087533255 @default.
• W4287094865 cites W3126968972 @default.
• W4287094865 cites W3164106051 @default.
• W4287094865 cites W3168727152 @default.
• W4287094865 cites W3195533500 @default.
• W4287094865 doi "https://doi.org/10.1016/j.clinthera.2022.07.007" @default.
• W4287094865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35940940" @default.
• W4287094865 hasPublicationYear "2022" @default.
• W4287094865 type Work @default.
• W4287094865 citedByCount "3" @default.
• W4287094865 countsByYear W42870948652022 @default.
• W4287094865 countsByYear W42870948652023 @default.
• W4287094865 crossrefType "journal-article" @default.
• W4287094865 hasAuthorship W4287094865A5027165022 @default.
• W4287094865 hasAuthorship W4287094865A5034887228 @default.
• W4287094865 hasAuthorship W4287094865A5040798720 @default.
• W4287094865 hasAuthorship W4287094865A5053168114 @default.
• W4287094865 hasAuthorship W4287094865A5090884900 @default.
• W4287094865 hasBestOaLocation W42870948651 @default.
• W4287094865 hasConcept C105795698 @default.
• W4287094865 hasConcept C121955636 @default.
• W4287094865 hasConcept C126322002 @default.
• W4287094865 hasConcept C133462117 @default.
• W4287094865 hasConcept C142724271 @default.
• W4287094865 hasConcept C144133560 @default.
• W4287094865 hasConcept C162324750 @default.
• W4287094865 hasConcept C162853370 @default.
• W4287094865 hasConcept C166957645 @default.
• W4287094865 hasConcept C187736073 @default.
• W4287094865 hasConcept C195487862 @default.
• W4287094865 hasConcept C197934379 @default.
• W4287094865 hasConcept C2524010 @default.
• W4287094865 hasConcept C2778476105 @default.
• W4287094865 hasConcept C2779134260 @default.
• W4287094865 hasConcept C3008058167 @default.
• W4287094865 hasConcept C33923547 @default.
• W4287094865 hasConcept C524204448 @default.
• W4287094865 hasConcept C57658597 @default.
• W4287094865 hasConcept C71924100 @default.
• W4287094865 hasConcept C85079727 @default.
• W4287094865 hasConcept C89623803 @default.
• W4287094865 hasConcept C90673727 @default.
• W4287094865 hasConcept C95457728 @default.
• W4287094865 hasConceptScore W4287094865C105795698 @default.
• W4287094865 hasConceptScore W4287094865C121955636 @default.
• W4287094865 hasConceptScore W4287094865C126322002 @default.
• W4287094865 hasConceptScore W4287094865C133462117 @default.
• W4287094865 hasConceptScore W4287094865C142724271 @default.
• W4287094865 hasConceptScore W4287094865C144133560 @default.
• W4287094865 hasConceptScore W4287094865C162324750 @default.
• W4287094865 hasConceptScore W4287094865C162853370 @default.
• W4287094865 hasConceptScore W4287094865C166957645 @default.
• W4287094865 hasConceptScore W4287094865C187736073 @default.
• W4287094865 hasConceptScore W4287094865C195487862 @default.
• W4287094865 hasConceptScore W4287094865C197934379 @default.
• W4287094865 hasConceptScore W4287094865C2524010 @default.
• W4287094865 hasConceptScore W4287094865C2778476105 @default.
• W4287094865 hasConceptScore W4287094865C2779134260 @default.
• W4287094865 hasConceptScore W4287094865C3008058167 @default.
• W4287094865 hasConceptScore W4287094865C33923547 @default.
• W4287094865 hasConceptScore W4287094865C524204448 @default.
• W4287094865 hasConceptScore W4287094865C57658597 @default.
• W4287094865 hasConceptScore W4287094865C71924100 @default.
• W4287094865 hasConceptScore W4287094865C85079727 @default.
• W4287094865 hasConceptScore W4287094865C89623803 @default.
• W4287094865 hasConceptScore W4287094865C90673727 @default.
• W4287094865 hasConceptScore W4287094865C95457728 @default.
• W4287094865 hasIssue "9" @default.
• W4287094865 hasLocation W42870948651 @default.
• W4287094865 hasLocation W42870948652 @default.
• W4287094865 hasLocation W42870948653 @default.
• W4287094865 hasOpenAccess W4287094865 @default.
• W4287094865 hasPrimaryLocation W42870948651 @default.
• W4287094865 hasRelatedWork W2174438959 @default.
• W4287094865 hasRelatedWork W2350086902 @default.
• W4287094865 hasRelatedWork W2543545203 @default.
• W4287094865 hasRelatedWork W281246900 @default.
• W4287094865 hasRelatedWork W3119540162 @default.
• W4287094865 hasRelatedWork W3152606407 @default.
• W4287094865 hasRelatedWork W3152916563 @default.
• W4287094865 hasRelatedWork W4206062546 @default.
• W4287094865 hasRelatedWork W4313474620 @default.
• W4287094865 hasRelatedWork W4381942459 @default.
• W4287094865 hasVolume "44" @default.
• W4287094865 isParatext "false" @default.

• next